DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/dp2ht3/triple_analysis) has announced the addition of the "Triple Analysis: Leukemia, Melanoma and Peptides" report to their offering.
This triple analysis focuses on cancer drug development strategies in both Leukemia and Melanoma and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.
Synopsis
Part I: Leukemia
based on the publication: 'A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market'
The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and eight subindications of leukemia.
Part II: Melanoma
based on the publication: 'Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?'
The melanoma drug report part comprises defined and up to date development strategies for 282 drugs within the portfolio of 164 companies world-wide, from Ceased to Marketed. The report extensively analyses their 226 identified drug targets, organized into 187 drug target strategies, and assesses them in melanoma.
Part III: Peptides
based on the publication: 'Cancer Peptides: From First-in-Class to Best-in-Class?'
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
For more information visit http://www.researchandmarkets.com/research/dp2ht3/triple_analysis
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
